1 Min Read
Nov 2 (Reuters) - Trillium Therapeutics Inc
* Trillium therapeutics advances TTI-621 into phase 1b cohort expansion enrollment Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.